Skip to content

Non-invasive Diagnostics of Iron Deficiency in Surgical Patients by Measuring Zinc Protoporphyrin-IX

Non-invasive Diagnostics of Iron Deficiency in Surgical Patients by Measuring Zinc Protoporphyrin-IX

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03071497
Enrollment
300
Registered
2017-03-07
Start date
2017-03-03
Completion date
2018-05-01
Last updated
2018-07-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anemia, Iron-deficiency, Iron Deficiency Anemia

Keywords

Iron-deficiency, Anemia, Iron-deficiency Anemia, Zinc protoporphyrin

Brief summary

* In approx. 40% of the incidences anemia is caused by iron deficiency (= ID). In turn, preoperative iron-deficiency anemia (= IDA) is associated with an increase in morbidity and mortality as well as with the need for a blood transfusion. * A successful preoperative treatment of IDA via iron supplementation requires a timely screening of iron deficiency, typically done by analyzing specific blood parameters. This however of course requires drawing a blood sample which further reduces the patients' blood volume and is in many cases stated as an inconvenient procedure. * Measured in blood zinc protoporphyrin-IX (= ZnPP) is an established parameter to detect ID. * This study aims to evaluate a prototype device detecting ZnPP non-invasively in the intact oral mucosa of surgical patients. * Results from the non-invasive measurement will be compared to reference measurements of ZnPP from residual blood samples (HPLC analysis) as well as to other parameters including Hb level and iron profile (MCH \[= mean corpuscular hemoglobin\], MCV \[= mean corpuscular volume\], ferritin, transferrin, transferrin saturation, soluble transferrin receptor, CRP).

Detailed description

The non-invasive measurements will be performed using a prototype device based on fluorescence spectroscopical techniques. In brief, light (restricted wavelengths: 407 / 425nm) will be used to excite ZnPP molecules within the blood of the oral mucosa by means of an optical fibre prob. The outgoing fluorescence emission of the excited molecules will be analyzed using a spectrometer and converted to a ZnPP value \[unit: µmol/mol heme\] using mathematical transformations as well as spectral fitting. This study compares the diagnostic performance of iron deficiency based on non-invasive measurements of Zinc protoporphyrin with results based on standard laboratory procedure (i.e. ZnPP measured in whole blood sample using HPLC) and blood values assessed during clinical routine, respectively. If results of non-invasive and reference measurement techniques yield coinciding results, the non-invasive method could provide an improved mean to detect iron deficiency and thereby to improve treatment of patients suffering from iron deficiency anemia.

Interventions

DIAGNOSTIC_TESTNon-invasive analysis of Zinc protoporphyrin

In patients fitting the inclusion criteria Zinc protoporphyrin will be measured non-invasively as proxy for iron deficiency. Results will be compared to ZnPP reference values measured via HPLC and with spectroscopical measurements performed on whole blood as well as with blood values (HB, MCH, MCV, ferritin, CRP, transferrin saturation, soluble transferrin receptor) assessed during clinical routine.

Sponsors

Ludwig-Maximilians - University of Munich
CollaboratorOTHER
Johann Wolfgang Goethe University Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Age \> 18 years

Exclusion criteria

* Patients who received a blood transfusion less than 8 weeks before examination * Pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Zinc protoporphyrin blood concentration (non-invasive measurement)BaselineUsing the prototype device Zinc protoporphyrin blood concentration \[unit: µmol/mol heme\] will be measured non-invasively in the oral mucosa. Concentrations will be compared (Spearman's Rho, sensitivity, specificity) with Zinc protoporphyrin measurements of whole blood samples (see outcome 2 and 3).

Secondary

MeasureTime frameDescription
Zinc protoporphyrin blood concentration (HPLC reference measurement)BaselineUsing HPLC, the analytical reference method, Zinc protoporphyrin blood concentration \[unit: µmol/mol heme\] will be measured in whole blood samples.
Zinc protoporphyrin blood concentration (spectroscopic measurement)BaselineUsing fluorescence spectroscopic methods Zinc protoporphyrin blood concentration \[unit: µmol/mol heme\] will be measured in whole blood samples.

Other

MeasureTime frameDescription
FerritinBaselineFerritin \[unit: µg/L\] will be assessed from blood samples using standardized laboratory techniques. Ferritin levels will be compared with non-invasive Zinc protoporphyrin measurements (Spearman's Rho, sensitivity, specificity).
CRPBaselineCRP (= C-reactive protein) \[unit: mg/dL\] will be assessed from blood samples using standardized laboratory techniques. CRP will be compared with non-invasive Zinc protoporphyrin measurements (Spearman's Rho, sensitivity, specificity).
HemoglobinBaselineHemoglobin levels \[unit: g/dL\] will be assessed from blood samples using standardized laboratory techniques. Hemoglobin levels will be compared with non-invasive Zinc protoporphyrin measurements (Spearman's Rho, sensitivity, specificity).
Soluble transferrin receptorBaselineSoluble Transferrin receptor \[unit: mg/L\] will be assessed from blood samples using standardized laboratory techniques. Soluble transferrin receptor will be compared with non-invasive Zinc protoporphyrin measurements (Spearman's Rho, sensitivity, specificity).
Transferrin saturationBaselineTransferrin saturation \[unit: %\] will be assessed from blood samples using standardized laboratory techniques. Transferrin saturation will be compared with non-invasive Zinc protoporphyrin measurements (Spearman's Rho, sensitivity, specificity).
MCHBaselineMCH (= mean corpuscular hemoglobin) \[unit: pg\] will be assessed from blood samples using standardized laboratory techniques. MCH will be compared with non-invasive Zinc protoporphyrin measurements (Spearman's Rho, sensitivity, specificity).
MCVBaselineMCV (= mean cell volume) \[unit: fL = femtoliter\] will be assessed from blood samples using standardized laboratory techniques. MCV will be compared with non-invasive Zinc protoporphyrin measurements (Spearman's Rho, sensitivity, specificity).

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026